Human Genome Epidemiology Literature Finder
|
Records 1 - 11 (of 11 Records) |
| Query Trace: Disease Progression and AKT1[original query] |
|---|
| PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands) 2011 Jan 71 (1): 82-8. Pu Xia, Hildebrandt Michelle A T, Lu Charles, Lin Jie, Stewart David J, Ye Yuanqing, Gu Jian, Spitz Margaret R, Wu Xife |
| Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pacific journal of cancer prevention : APJCP 2012 13 (5): 2157-62. Xu Jia-Li, Wang Zhen-Wu, Hu Ling-Min, Yin Zhi-Qiang, Huang Ming-De, Hu Zhi-Bin, Shen Hong-Bing, Shu Yong-Qi |
| A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer 2016 Sep . Makker Vicky, Recio Fernando O, Ma Ling, Matulonis Ursula A, Lauchle Jennifer O, Parmar Hema, Gilbert Houston N, Ware Joseph A, Zhu Rui, Lu Shan, Huw Ling-Yuh, Wang Yulei, Koeppen Hartmut, Spoerke Jill M, Lackner Mark R, Aghajanian Carol |
| Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC cancer 2016 Nov 16 (1): 864. Ko Ryo, Kenmotsu Hirotsugu, Serizawa Masakuni, Koh Yasuhiro, Wakuda Kazushige, Ono Akira, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Isaka Mitsuhiro, Endo Masahiro, Nakajima Takashi, Ohde Yasuhisa, Yamamoto Nobuyuki, Takahashi Kazuhisa, Takahashi Toshia |
| Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. Molecular cancer 2018 Feb 17 (1): 67. Takeshita Takashi, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Tomiguchi Mai, Sueta Aiko, Murakami Keiichi, Iwase Hirota |
| Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct . Pearson Alex, Proszek Paula, Pascual Javier, Fribbens Charlotte, Shamsher Monee K, Kingston Belinda, O'Leary Ben, Herrera-Abreu Maria T, Cutts Rosalind J, Garcia-Murillas Isaac, Bye Hannah, Walker Brian A, Gonzalez De Castro David, Yuan Lina, Jamal Sabri, Hubank Mike, Lopez-Knowles Elena, Schuster Eugene F, Dowsett Mitch, Osin Peter, Nerurkar Ashutosh, Parton Marina, Okines Alicia F C, Johnston Stephen R D, Ring Alistair, Turner Nicholas |
| Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA oncology 2020 12 7 (2): 271-278. Kalinsky Kevin, Hong Fangxin, McCourt Carolyn K, Sachdev Jasgit C, Mitchell Edith P, Zwiebel James A, Doyle L Austin, McShane Lisa M, Li Shuli, Gray Robert J, Rubinstein Larry V, Patton David, Williams Paul M, Hamilton Stanley R, Conley Barbara A, O'Dwyer Peter J, Harris Lyndsay N, Arteaga Carlos L, Chen Alice P, Flaherty Keith |
| Prognosis and Genomic Landscape of Liver Metastasis in Patients With Breast Cancer. Frontiers in oncology 2021 3 11 588136. Tian Chonglin, Liu Sujing, Wang Yongsheng, Song Xianra |
| PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. British journal of cancer 2021 3 124 (9): 1581-1591. Gris-Oliver Albert, Ibrahim Yasir H, Rivas Martín A, García-García Celina, Sánchez-Guixé Mònica, Ruiz-Pace Fiorella, Viaplana Cristina, Pérez-García José M, Llombart-Cussac Antonio, Grueso Judit, Parés Mireia, Guzmán Marta, Rodríguez Olga, Anton Pilar, Cozar Patricia, Calvo Maria Teresa, Bruna Alejandra, Arribas Joaquín, Caldas Carlos, Dienstmann Rodrigo, Nuciforo Paolo, Oliveira Mafalda, Cortés Javier, Serra Viole |
| Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 7 . Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Barrios, Joyce O'Shaughnessy, Steven J Isakoff, Shigehira Saji, Ruffo Freitas-Junior, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J Wongchenko, Sarah-Jayne Reilly, Nicholas Turn |
| A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors. Biomedicines 2024 10 12 (10): . Alessandra Virga, Caterina Gianni, Michela Palleschi, Davide Angeli, Filippo Merloni, Roberta Maltoni, Paola Ulivi, Giovanni Martinelli, Ugo De Giorgi, Sara Bravacci |
- Page last reviewed:Feb 1, 2024
- Content source: